Drug Design Development And Therapy
SCIE國際簡稱：DRUG DES DEV THER 參考譯名：藥物設計開發和治療
主要研究方向：CHEMISTRY, MEDICINAL-PHARMACOLOGY & PHARMACY 非預警期刊 審稿周期： 12周，或約稿
《藥物設計開發和治療》(Drug Design Development And Therapy)是一本由Dove Medical Press Ltd.出版的以CHEMISTRY, MEDICINAL-PHARMACOLOGY & PHARMACY為研究特色的國際期刊，發表該領域相關的原創研究文章、評論文章和綜述文章，及時報道該領域相關理論、實踐和應用學科的最新發現，旨在促進該學科領域科學信息的快速交流。該期刊是一本開放期刊，近三年沒有被列入預警名單。該期刊享有很高的科學聲譽，影響因子不斷增加，發行量也同樣高。
Drug Design, Development and Therapy is an international, peer-reviewed, open access journal that spans the spectrum of drug design, discovery and development through to clinical applications.
The journal is characterized by the rapid reporting of high-quality original research, reviews, expert opinions, commentary and clinical studies in all therapeutic areas.
Specific topics covered by the journal include:
Drug target identification and validation
Phenotypic screening and target deconvolution
Biochemical analyses of drug targets and their pathways
New methods or relevant applications in molecular/drug design and computer-aided drug discovery*
Design, synthesis, and biological evaluation of novel biologically active compounds (including diagnostics or chemical probes)
Structural or molecular biological studies elucidating molecular recognition processes
Fragment-based drug discovery
Pharmaceutical/red biotechnology
Isolation, structural characterization, (bio)synthesis, bioengineering and pharmacological evaluation of natural products**
Distribution, pharmacokinetics and metabolic transformations of drugs or biologically active compounds in drug development
Drug delivery and formulation (design and characterization of dosage forms, release mechanisms and in vivo testing)
Preclinical development studies
Translational animal models
Mechanisms of action and signalling pathways
Toxicology
Gene therapy, cell therapy and immunotherapy
Personalized medicine and pharmacogenomics
Clinical drug evaluation
Patient safety and sustained use of medicines.
Drug Design Development And Therapy期刊信息
- ISSN：1177-8881
- 出版語言：English
- 是否OA：開放
- 出版地區：ENGLAND
- 是否預警：否
- 出版商：Dove Medical Press Ltd.
- 出版周期：1 issue/year
- 創刊時間：2007
- 開源占比：0.9689
- Gold OA文章占比：97.50%
- OA被引用占比：1
- 出版國人文章占比：0.52
- 出版撤稿占比：0.0043...
- 研究類文章占比：80.08%
Drug Design Development And Therapy CiteScore評價數據（2024年最新版）
| CiteScore | SJR | SNIP | CiteScore 指數 | ||||||||||||||||
| 9 | 0.999 | 1.124 |
|
名詞解釋：CiteScore 是衡量期刊所發表文獻的平均受引用次數，是在 Scopus 中衡量期刊影響力的另一個指標。當年CiteScore 的計算依據是期刊最近4年（含計算年度）的被引次數除以該期刊近四年發表的文獻數。例如，2022年的 CiteScore 計算方法為：2022年的 CiteScore =2019-2022年收到的對2019-2022年發表的文件的引用數量÷2019-2022年發布的文獻數量 注：文獻類型包括：文章、評論、會議論文、書籍章節和數據論文。
Drug Design Development And Therapy中科院評價數據
中科院 2023年12月升級版
| Top期刊 | 綜述期刊 | 大類學科 | 小類學科 | ||
| 否 | 否 | 醫學 | 2區 | CHEMISTRY, MEDICINAL 藥物化學 PHARMACOLOGY & PHARMACY 藥學 | 2區 2區 |
中科院 2022年12月升級版
| Top期刊 | 綜述期刊 | 大類學科 | 小類學科 | ||
| 否 | 否 | 醫學 | 3區 | CHEMISTRY, MEDICINAL 藥物化學 PHARMACOLOGY & PHARMACY 藥學 | 2區 3區 |
中科院 2021年12月舊的升級版
| Top期刊 | 綜述期刊 | 大類學科 | 小類學科 | ||
| 否 | 否 | 醫學 | 3區 | CHEMISTRY, MEDICINAL 藥物化學 PHARMACOLOGY & PHARMACY 藥學 | 3區 3區 |
中科院 2021年12月基礎版
| Top期刊 | 綜述期刊 | 大類學科 | 小類學科 | ||
| 否 | 否 | 醫學 | 3區 | CHEMISTRY, MEDICINAL 藥物化學 PHARMACOLOGY & PHARMACY 藥學 | 3區 3區 |
中科院 2021年12月升級版
| Top期刊 | 綜述期刊 | 大類學科 | 小類學科 | ||
| 否 | 否 | 醫學 | 3區 | CHEMISTRY, MEDICINAL 藥物化學 PHARMACOLOGY & PHARMACY 藥學 | 3區 3區 |
中科院 2020年12月舊的升級版
| Top期刊 | 綜述期刊 | 大類學科 | 小類學科 | ||
| 否 | 否 | 醫學 | 3區 | CHEMISTRY, MEDICINAL 藥物化學 PHARMACOLOGY & PHARMACY 藥學 | 3區 3區 |
Drug Design Development And Therapy JCR評價數據（2023-2024年最新版）
| 按JIF指標學科分區 | 收錄子集 | 分區 | 排名 | 百分位 |
| 學科：CHEMISTRY, MEDICINAL | SCIE | Q1 | 17 / 72 |
77.1% |
| 學科：PHARMACOLOGY & PHARMACY | SCIE | Q1 | 55 / 354 |
84.6% |
| 按JCI指標學科分區 | 收錄子集 | 分區 | 排名 | 百分位 |
| 學科：CHEMISTRY, MEDICINAL | SCIE | Q1 | 17 / 72 |
77.08% |
| 學科：PHARMACOLOGY & PHARMACY | SCIE | Q1 | 68 / 354 |
80.93% |
Drug Design Development And Therapy歷年數據統計
影響因子
中科院分區
Drug Design Development And Therapy中國學者發文選摘
-
1、Binary Nanodrug-Delivery System Designed for Leukemia Therapy: Aptamer- and Transferrin-Codecorated Daunorubicin- and Luteolin-Coloaded Nanoparticles
Author: Zhu, Yuanyuan; Zhang, Wei; Chen, Jing
Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2023; Vol. 17, Issue , pp. 1-13. DOI: 10.2147/DDDT.S387246
-
2、Menthone Exerts its Antimicrobial Activity Against Methicillin Resistant Staphylococcus aureus by Affecting Cell Membrane Properties and Lipid Profile
Author: Zhao, Wenming; Yang, Chengwei; Zhang, Ning; Peng, Yuanyuan; Ma, Ying; Gu, Keru; Liu, Xia; Liu, Xiaohui; Liu, Xijian; Liu, Yumin; Li, Songkai; Zhao, Linjing
Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2023; Vol. 17, Issue , pp. 219-236. DOI: 10.2147/DDDT.S384716
-
3、Evaluation of Chitosan-Oleuropein Nanoparticles on the Durability of Dentin Bonding
Author: Zhao, Shuya; Zhang, Yunyang; Chen, Yun; Xing, Xianghui; Wang, Yu; Wu, Guofeng
Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2023; Vol. 17, Issue , pp. 167-180. DOI: 10.2147/DDDT.S390039
-
4、Efficacy and Mechanism of Qianshan Huoxue Gao in Acute Coronary Syndrome via Regulation of Intestinal Flora and Metabolites
Author: Zhao, Ning; Ma, Yan; Liang, Xiaoxue; Zhang, Yu; Hong, Dacheng; Wang, Ying; Bai, Dong
Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2023; Vol. 17, Issue , pp. 579-595. DOI: 10.2147/DDDT.S396649
-
5、Network Pharmacology and Experimental Validation to Explore the Effect and Mechanism of Kanglaite Injection Against Triple-Negative Breast Cancer
Author: Zhao, Mei; Fu, Lijuan; Xu, Panling; Wang, Ting; Li, Ping
Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2023; Vol. 17, Issue , pp. 901-917. DOI: 10.2147/DDDT.S397969
-
6、Network Pharmacology and Experimental Validation to Explore That Celastrol Targeting PTEN is the Potential Mechanism of Tripterygium wilfordii (L?v.) Hutch Against IgA Nephropathy
Author: Zhao, Juanyong; Liu, Haiyang; Xia, Ming; Chen, Qian; Wan, Lili; Leng, Bin; Tang, Chengyuan; Chen, Guochun; Liu, Yu; Zhang, Lei; Liu, Hong
Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2023; Vol. 17, Issue , pp. 887-900. DOI: 10.2147/DDDT.S402503
-
7、Shensong Yangxin Capsule Reduces the Susceptibility of Arrhythmia in db/db Mice via Inhibiting the Inflammatory Response Induced by Endothelium Dysfunction
Author: Zhang, Jiehan; Li, Hongrong; Wang, Dandong; Gu, Jiaojiao; Hou, Yunlong; Wu, Yiling
Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2023; Vol. 17, Issue , pp. 313-330. DOI: 10.2147/DDDT.S392328
-
8、Review on the Diverse Biological Effects of Glabridin
Author: Zhang, Jianhong; Wu, Xinhui; Zhong, Baiyin; Liao, Qicheng; Wang, Xin; Xie, Yuankang; He, Xiao
Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2023; Vol. 17, Issue , pp. 15-37. DOI: 10.2147/DDDT.S385981
Drug Design Development And Therapy同類期刊
-
公共衛生前沿
Frontiers In Public Health
中科院 3區 JCR Q2
-
藥理學前沿
Frontiers In Pharmacology
中科院 2區 JCR Q1
-
生物醫學與藥物治療
Biomedicine & Pharmacotherapy
中科院 2區 JCR Q1
-
探索腫瘤學
Discover Oncology
中科院 4區 JCR Q2
-
Bmc精神病學
Bmc Psychiatry
中科院 2區 JCR Q2
-
材料化學雜志 B
Journal Of Materials Chemistry B
中科院 3區 JCR Q1
-
Bmc神經病學
Bmc Neurology
中科院 3區 JCR Q3
-
美康
Medcomm
中科院 3區 JCR Q1
免責聲明
若用戶需要出版服務，請聯系出版商：PO BOX 300-008, ALBANY, NEW ZEALAND, AUCKLAND, 0752。